RxDoctor Payments Data

David Baidal, MD

Endocrinology, Diabetes & Metabolism · Miami, FLNPI 1487896643

Payments from drug & device makers

$50,570in general payments, 2019–2025

Across 23 payments — averaging $2198.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$24K
  • Sanofi$20K
  • Vertex$5K
  • Medtronic$750
  • BETA Bionics, Inc.$218
  • Tandem Diabetes Care, Inc.$116
  • plus $179 from 5 others
$2,091in research payments, 2019–2025

Across 1 payment — averaging $2091.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$2K

What the payments were for

  • Consulting fees$4,72377%
  • Speaking & faculty fees$75012%
  • Travel & lodging$1022%
  • Food & beverage$4577%
  • Education$651%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,570 in reported general payments places this provider in the 85th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$16,309
Medicare patients
83
Services billed
215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$59,144
TrulicityDulaglutide29$50,202
MounjaroTirzepatide28$37,000
JardianceEmpagliflozin22$29,414
JanuviaSitagliptin Phosphate15$18,736
Tresiba Flextouch U-100Insulin Degludec23$17,195
Novolog FlexpenInsulin Aspart23$8,627
Nano 2nd Gen Pen NeedlePen Needle, Diabetic37$3,954
HumalogInsulin Lispro12$3,287
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,062
SynthroidLevothyroxine Sodium15$1,981
Levothyroxine Sodium29$586
Atorvastatin Calcium41$428
Gabapentin22$378
Metformin Hcl38$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$65$59,14444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →